Mesoblast (NASDAQ:MESO) Shares Gap Down – Here’s Why

Posted by Stanley Muller on Jul 17th, 2026

Mesoblast Limited (NASDAQ:MESO – Get Free Report) gapped down before the market opened on Friday . The stock had previously closed at $17.86, but opened at $16.48. Mesoblast shares last traded at $16.83, with a volume of 50,113 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Mesoblast in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Mesoblast currently has a consensus rating of “Hold”.

View Our Latest Stock Report on Mesoblast

Mesoblast Stock Performance

The company has a debt-to-equity ratio of 0.10, a current ratio of 1.58 and a quick ratio of 1.41. The firm has a market capitalization of $2.24 billion, a PE ratio of -61.62 and a beta of 2.08. The company’s fifty day simple moving average is $14.74 and its 200 day simple moving average is $15.80.

Institutional Trading of Mesoblast

Institutional investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Mesoblast by 30.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,383 shares of the company’s stock worth $43,000 after buying an additional 558 shares during the period. GAMMA Investing LLC raised its holdings in Mesoblast by 14.1% during the 2nd quarter. GAMMA Investing LLC now owns 7,413 shares of the company’s stock valued at $100,000 after acquiring an additional 916 shares during the period. JPMorgan Chase & Co. raised its holdings in Mesoblast by 55.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,831 shares of the company’s stock valued at $46,000 after acquiring an additional 1,012 shares during the period. Choreo LLC lifted its position in shares of Mesoblast by 15.1% during the fourth quarter. Choreo LLC now owns 12,225 shares of the company’s stock worth $227,000 after acquiring an additional 1,600 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of Mesoblast during the fourth quarter worth $32,000. 1.43% of the stock is currently owned by hedge funds and other institutional investors.

Mesoblast Company Profile

(Get Free Report)

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.